By Richard Daifuku : Ferric citrate is being developed as a phosphate binder by Keryx Biopharmaceuticals ( KERX ) for the treatment of hyperphosphatemia in patients with chronic kidney disease [CDK] on dialysis, with a PDUFA date of June
(Reuters) - Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the...
By Quoth the Raven : Introduction In an effort to find niche investing moves that I feel most traders don't take advantage of, I spent a day brainstorming with a friend of mine over some of the lesser used "tricks" we sometimes use to invest. These are small items that we've learned over time that
By EnhydrisPECorp : Shares of Keryx Biopharmaceuticals ( KERX ) have been on a wild ride since ..... price of $12 a share . Although KERX certainly looks like a strong ..... in this article why I believe KERX is a short candidate, and the
(Reuters) - Keryx Biopharmaceuticals Inc and Aeterna Zentaris said their experimental colorectal cancer drug did not meet the main goal of a late-stage trial, raising doubts on the drug's future as a...
We are no longer providing equity research on Keryx Biopharmaceuticals KERX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We are putting our fair value estimate for Keryx Biopharmaceuticals KERX under review after the company released positive Phase II clinical trial data on KRX-0401 (perifosine) when used to treat advance
We are maintaining our fair value estimate after reviewing Keryx Biopharmaceuticals ' KERX year-end results. Despite efforts to cut costs, the firm's limited revenue stream was no match for the $52.3 million in
With Keryx Biopharmaceuticals ' KERX fourth-quarter results around the corner, we are reiterating our opinion that the firm is a speculative investment. Costly
After reviewing Keryx Biopharmaceuticals ' KERX third-quarter earnings, we are maintaining our fair value estimate. With only $368,000 in license and service revenue and